Ozempic vs. Wegovy for Weight Loss: What Is the Difference?

What is the actual difference between Ozempic and Wegovy?

Ozempic and Wegovy are both brand names for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone the gut releases after eating; semaglutide mimics it to slow stomach emptying, reduce appetite, and signal satiety to the brain 1Ref 1Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.STEP 1 trial: semaglutide 2.4 mg produced mean 14.9% weight loss vs 2.4% placebo over 68 weeks in adults without type 2 diabetes; 86% achieved ≥5% weight loss.

The two drugs share identical chemistry, identical injection route (weekly subcutaneous injection), and identical side-effect profile. What differs is the regulatory approval and the dose ceiling:

• Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg weekly) is FDA-approved for lowering blood sugar in adults with type 2 diabetes, and for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease 2Ref 2Novo Nordisk (2024).WEGOVY (semaglutide) injection — FDA Prescribing Information.FDA-approved indications for Wegovy (weight management, cardiovascular risk reduction), maximum dose 2.4 mg weekly, contraindications including MTC history and MEN 2, and key safety warnings.
• Wegovy (semaglutide 2.4 mg weekly at maintenance) is FDA-approved for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes 2Ref 2Novo Nordisk (2024).WEGOVY (semaglutide) injection — FDA Prescribing Information.FDA-approved indications for Wegovy (weight management, cardiovascular risk reduction), maximum dose 2.4 mg weekly, contraindications including MTC history and MEN 2, and key safety warnings. The FDA later expanded Wegovy's label to include cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight — a finding supported by the large SELECT trial 4Ref 4Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.SELECT trial: semaglutide 2.4 mg reduced major cardiovascular events by 20% versus placebo in 17,604 adults with obesity/overweight and established cardiovascular disease but without diabetes, supporting FDA label expansion and Medicare coverage change.

The approved maximum maintenance dose for Wegovy (2.4 mg weekly) is higher than the current approved ceiling for Ozempic (2 mg weekly). The weight-loss evidence base was built using the Wegovy dose.

What did the clinical trials actually show?

The landmark STEP 1 trial enrolled 1,961 adults with obesity or overweight without type 2 diabetes and randomized them 2:1 to semaglutide 2.4 mg or placebo, both with lifestyle counseling. After 68 weeks, participants receiving semaglutide lost a mean of 14.9% of their body weight compared to 2.4% with placebo; 86% achieved at least 5% weight loss 1Ref 1Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.STEP 1 trial: semaglutide 2.4 mg produced mean 14.9% weight loss vs 2.4% placebo over 68 weeks in adults without type 2 diabetes; 86% achieved ≥5% weight loss.

The STEP 5 trial, the longest of the STEP program at 104 weeks, showed that weight loss was durable across two years, with a mean reduction of 15.2% in the semaglutide group versus 2.6% in the placebo group 3Ref 3Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S (2022).Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.STEP 5 trial: sustained weight loss of mean 15.2% with semaglutide 2.4 mg vs 2.6% with placebo over 104 weeks, establishing durable long-term efficacy.

For the diabetes indication, the SUSTAIN-6 trial demonstrated that semaglutide (at doses used in Ozempic) reduced the rate of major adverse cardiovascular events — cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke — by a relative 26% versus placebo over a median 2.1 years in people with type 2 diabetes at high cardiovascular risk 5Ref 5Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T (2016).Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.SUSTAIN-6 trial: semaglutide at Ozempic doses reduced major adverse cardiovascular events by 26% versus placebo over median 2.1 years in adults with type 2 diabetes at high cardiovascular risk, supporting the cardiovascular indication for Ozempic.

The SELECT trial extended cardiovascular evidence to people without diabetes: in 17,604 adults with pre-existing cardiovascular disease and obesity or overweight but no diabetes, semaglutide 2.4 mg reduced major cardiovascular events by 20% over a mean 39.8 months versus placebo 4Ref 4Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.SELECT trial: semaglutide 2.4 mg reduced major cardiovascular events by 20% versus placebo in 17,604 adults with obesity/overweight and established cardiovascular disease but without diabetes, supporting FDA label expansion and Medicare coverage change.

What happens if you stop taking it?

This is among the most important things to understand before starting. The STEP 1 extension study followed participants for one year after the 68-week active treatment ended. Those who had taken semaglutide regained approximately two-thirds of their prior weight loss within 12 months of stopping, and most cardiometabolic gains reversed toward baseline 6Ref 6Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF (2022).Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.STEP 1 extension: participants regained approximately two-thirds of prior weight loss within one year of stopping semaglutide, with cardiometabolic gains largely reversing to baseline.

This reflects semaglutide's mechanism — it works while you take it but does not permanently reset appetite or metabolism. Clinicians generally treat obesity as a chronic condition requiring long-term management, similar to treating hypertension or diabetes. Stopping the medication after reaching a weight goal, without a long-term maintenance plan, typically results in substantial weight regain. This is an important conversation to have with a clinician before starting.

Why do clinicians sometimes prescribe Ozempic for weight loss instead of Wegovy?

Clinicians can legally prescribe any medication for uses other than its FDA approval — this is called off-label prescribing and is a routine, legal part of medical practice. Several practical factors have led some clinicians to prescribe Ozempic off-label for weight management:

Insurance coverage gaps. Ozempic, as a diabetes drug, has historically been more broadly covered by commercial and government insurance plans for people with a type 2 diabetes diagnosis. Wegovy's coverage for weight management has been inconsistent and often requires prior authorization with documentation of failed prior attempts.

Wegovy supply shortages. During periods of manufacturing shortage, Wegovy has been difficult to obtain, while Ozempic supply has been more stable.

Coverage change for cardiovascular indication. Following the SELECT trial results, the FDA expanded Wegovy's approval to include cardiovascular risk reduction. Medicare Part D plans may now cover Wegovy when prescribed for cardiovascular risk reduction in eligible beneficiaries — a meaningful policy shift, though coverage still varies by plan 4Ref 4Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.SELECT trial: semaglutide 2.4 mg reduced major cardiovascular events by 20% versus placebo in 17,604 adults with obesity/overweight and established cardiovascular disease but without diabetes, supporting FDA label expansion and Medicare coverage change.

The trade-off when using Ozempic off-label is the lower available dose. The 14-15% mean weight loss seen in the STEP trials was achieved at the 2.4 mg Wegovy dose. When Ozempic is prescribed for weight loss, the clinician works within Ozempic's approved dose range, which may produce less weight loss on average.

What are the side effects, and are they different between the two?

Because they contain the same molecule, the side-effect profiles are essentially identical. The most common side effects are gastrointestinal and occur most frequently during dose increases 7Ref 7Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, Mosenzon O, Rubino DM, Thomsen M, Wadden TA, Pedersen SD (2022).Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Pooled STEP 1-3 analysis: nausea ~44%, diarrhea ~30%, vomiting ~25%, constipation ~24% with semaglutide vs placebo; most events mild-to-moderate, transient, and associated with dose escalation periods:

• Nausea (approximately 44% of participants in STEP 1-3 vs. 16% with placebo)
• Diarrhea (approximately 30% vs. 16% with placebo)
• Vomiting (approximately 25% vs. 6% with placebo)
• Constipation (approximately 24% vs. 11% with placebo)

Almost all gastrointestinal events in the trials were mild to moderate, non-serious, and transient — they occurred most often around dose increases and generally resolved. The graduated titration schedule (starting low and increasing slowly over several months) is designed to minimize these effects 7Ref 7Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, Mosenzon O, Rubino DM, Thomsen M, Wadden TA, Pedersen SD (2022).Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Pooled STEP 1-3 analysis: nausea ~44%, diarrhea ~30%, vomiting ~25%, constipation ~24% with semaglutide vs placebo; most events mild-to-moderate, transient, and associated with dose escalation periods.

Key contraindications (from FDA prescribing information) [2]: - Personal or family history of medullary thyroid carcinoma (MTC) - Multiple endocrine neoplasia syndrome type 2 (MEN 2) - Prior serious hypersensitivity reaction to semaglutide

Additional risks discussed in the prescribing information include acute pancreatitis, gallbladder disease (cholelithiasis and cholecystitis occurred at higher rates in treated participants than placebo), and changes in kidney function. These risks are reasons a thorough medical history before starting is essential.

What factors shape which option a clinician might consider?

No general article can substitute for an individual clinical evaluation. That said, several variables commonly shape the conversation:

Diagnosis. Whether you have type 2 diabetes, prediabetes, or neither affects which drug is on-label, how it is likely to be covered by insurance, and what the primary treatment goal is.

BMI and qualifying conditions. Wegovy's weight-management indication applies to adults with BMI ≥ 30, or BMI ≥ 27 with at least one qualifying weight-related condition. Meeting these thresholds matters for insurance approval.

Cardiovascular disease history. The SELECT trial demonstrated a 20% reduction in major cardiovascular events in people with established cardiovascular disease and obesity without diabetes 4Ref 4Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.SELECT trial: semaglutide 2.4 mg reduced major cardiovascular events by 20% versus placebo in 17,604 adults with obesity/overweight and established cardiovascular disease but without diabetes, supporting FDA label expansion and Medicare coverage change. This expands the evidence base and the insurance coverage rationale for Wegovy beyond weight reduction alone.

Kidney function. Baseline and ongoing kidney function monitoring is part of standard management with GLP-1 receptor agonists.

History of pancreatitis or gallbladder disease. Either warrants careful risk-benefit discussion with a clinician before starting.

Other medications. Semaglutide slows gastric emptying, which can affect absorption timing of oral medications, including oral contraceptives. Your full medication list matters.

Insurance and formulary. Coverage is the most practical constraint for many people. List prices without coverage are high. Checking your specific plan's formulary, prior authorization requirements, and what diagnoses are required to qualify is a necessary step — ideally before or alongside the clinical conversation.